WO2006027463A3 - Biochip for determining sensitivity to an anticancer drug - Google Patents

Biochip for determining sensitivity to an anticancer drug Download PDF

Info

Publication number
WO2006027463A3
WO2006027463A3 PCT/FR2005/002142 FR2005002142W WO2006027463A3 WO 2006027463 A3 WO2006027463 A3 WO 2006027463A3 FR 2005002142 W FR2005002142 W FR 2005002142W WO 2006027463 A3 WO2006027463 A3 WO 2006027463A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer drug
biochip
determining sensitivity
patient
relates
Prior art date
Application number
PCT/FR2005/002142
Other languages
French (fr)
Other versions
WO2006027463A2 (en
Inventor
Valerie Chabaud
Incan Chantal D
Valerie Sylvain-Vidal
Veronique Vidal
Marie Agier
Yves-Jean Bignon
Christian Pradeyrol
Original Assignee
Diagnogene Sa
Valerie Chabaud
Incan Chantal D
Valerie Sylvain-Vidal
Veronique Vidal
Marie Agier
Yves-Jean Bignon
Christian Pradeyrol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnogene Sa, Valerie Chabaud, Incan Chantal D, Valerie Sylvain-Vidal, Veronique Vidal, Marie Agier, Yves-Jean Bignon, Christian Pradeyrol filed Critical Diagnogene Sa
Publication of WO2006027463A2 publication Critical patent/WO2006027463A2/en
Publication of WO2006027463A3 publication Critical patent/WO2006027463A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The invention relates to a solid substrate coated with a set of fragments representative of genes whereof the expression profile in a patient with cancer enables the chemosensitivity or chemoresistance to at least one given anticancer drug to be predicted. The invention also relates to a kit comprising one such substrate, and to a method for the in vitro prediction of the therapeutic response from a tumorous specimen of one such patient, said method using the inventive solid substrate.
PCT/FR2005/002142 2004-08-30 2005-08-25 Biochip for determining sensitivity to an anticancer drug WO2006027463A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409192 2004-08-30
FR0409192A FR2874622B1 (en) 2004-08-30 2004-08-30 BIOPUCE FOR DETERMINING A SENSITIVITY TO AN ANTICANCER DRUG AND METHOD FOR USING SAME

Publications (2)

Publication Number Publication Date
WO2006027463A2 WO2006027463A2 (en) 2006-03-16
WO2006027463A3 true WO2006027463A3 (en) 2006-05-11

Family

ID=34948537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002142 WO2006027463A2 (en) 2004-08-30 2005-08-25 Biochip for determining sensitivity to an anticancer drug

Country Status (2)

Country Link
FR (1) FR2874622B1 (en)
WO (1) WO2006027463A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239223A1 (en) * 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
KR20090093959A (en) * 2006-10-23 2009-09-02 더 유에이비 리서치 파운데이션 Biomarkers for cancer sensitivity to an anti-cancer agent and uses thereof
CN113684275B (en) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 Methods and kits for predicting the response of esophageal cancer to anti-ERBB 3 antibody therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"GeneChip Human Genome U133 set", AFFYMETRIX, September 2001 (2001-09-01), US, XP002324895 *
BERTUCCI F ET AL: "Gene expression profiling of primary breast carcinomas using arrays of cancidate genes", 2000, HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, PAGE(S) 2981-2991, ISSN: 0964-6906, XP002225994 *
BUCHHOLZ THOMAS A ET AL: "Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.", CANCER JOURNAL (SUDBURY, MASS.) 2002 NOV-DEC, vol. 8, no. 6, November 2002 (2002-11-01), pages 461 - 468, XP009015206, ISSN: 1528-9117 *
CHANG JENNY C ET AL: "Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.", LANCET (NORTH AMERICAN EDITION), vol. 362, no. 9381, 2 August 2003 (2003-08-02), pages 362 - 369, XP004779018, ISSN: 0099-5355 *
DATABASE GENEANNOT Weizmann institute of science; "GeneChip Human Genome U133 set", XP002364457 *
IWAO-KOIZUMI K ET AL: "PREDICTION OF DOCETAXEL RESPONSE IN HUMAN BREAST CANCER BY GENE EXPRESSION PROFILING", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 23, no. 3, 20 January 2005 (2005-01-20), pages 422 - 431, XP009058742, ISSN: 0732-183X *
KIKUCHI T ET AL: "Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 22, 2003, pages 2192 - 2205, XP002304992, ISSN: 0950-9232 *
LACROIX M ET AL: "A low-density DNA microarray for analysis of markers in breast cancer.", THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. 2002 JAN-MAR, vol. 17, no. 1, January 2002 (2002-01-01), pages 5 - 23, XP008010290, ISSN: 0393-6155 *
MURAKAWA KATSUHIKO ET AL: "Prediction of lymph node metastasis and perineural invasion of biliary tract cancer by selected features from cDNA array data.", THE JOURNAL OF SURGICAL RESEARCH. DEC 2004, vol. 122, no. 2, December 2004 (2004-12-01), pages 184 - 194, XP002324727, ISSN: 0022-4804 *
NARAYANAN BHAGAVATHI A ET AL: "Comparison of the chemopreventive efficacies of 1,4-phenylenebis (methylene) selenocyanate (p-XSC) and its glutathione conjugate p-XSe-SG on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in the rat: Molecular mechanisms using microarray analysis", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 823, XP009046305, ISSN: 0197-016X *
YANG YEE HWA ET AL: "Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation.", NUCLEIC ACIDS RESEARCH. 15 FEB 2002, vol. 30, no. 4, 15 February 2002 (2002-02-15), pages E15.1 - E15.10, XP002324734, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
FR2874622B1 (en) 2011-01-14
FR2874622A1 (en) 2006-03-03
WO2006027463A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2007123772A3 (en) Genes involved in estrogen metabolism
WO2009050691A3 (en) Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2005070020A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
EP2420837A3 (en) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1985715A3 (en) ESR1 and cervical cancer
AU2002359823A1 (en) Prostate cancer diagnosis and outcome prediction by expression analysis
WO2010018601A3 (en) Genetic variants predictive of cancer risk
EP2113743A4 (en) Displacement measuring method, displacement measuring instrument, displacement measuring target and structure
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2006037462A3 (en) Cancer markers
EP2311879A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2008028968A3 (en) Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2007030611A3 (en) A calculated index of genomic expression of estrogen receptor (er) and er related genes
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2012028679A3 (en) Prognostic and/or predictive biomarkers and biological applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase